Tirzepatide

What Is Tirzepatide?

Tirzepatide is a synthetic peptide that activates two incretin receptors: the GIP receptor and the GLP-1 receptor. It was developed under the code LY3298176 for type 2 diabetes, obesity and nonalcoholic steatohepatitis.^[1]

Earlier incretin-based drugs such as semaglutide and dulaglutide act selectively on the GLP-1 receptor. Tirzepatide is described as a first-in-class dual agonist, and trials have reported improvements in glycemic control, body weight, blood pressure and lipid profile compared with placebo and with GLP-1 receptor agonists.^[2]

The compound is approved for type 2 diabetes and is also used as a reference molecule in research on dual and triple incretin agonists.^[3] Its clinical program extends to obesity-related complications, including sleep apnea, steatohepatitis and heart failure with preserved ejection fraction.^[4]

Chemical Structure and Molecular Identity

Tirzepatide is a 39-residue linear peptide modeled on the native GIP sequence, with two non-coded residues and a fatty-acid side chain. PubChem (CID 166567236) lists the molecular formula as C225H348N48O68 and the molecular weight as 4813 g/mol; the CAS Registry Number is 2023788-19-2.

Structural features

• Non-coded residues: alpha-aminoisobutyric acid (Aib) at positions 2 and 13.
• Lipidation: the lysine 20 side chain carries an eicosanedioic acid (C20 diacid) attached through a gamma-glutamic acid spacer and two 8-amino-3,6-dioxaoctanoic acid linkers.
• Termini: a free N-terminal tyrosine, as in native GIP, and a C-terminal serine amide.

A population pharmacokinetic model built from 19 pooled studies described tirzepatide with a two-compartment model and first-order absorption and elimination. Its half-life was about 5 days, and the model found that body size influenced exposure.^[3] Because of the Aib residues and the lipidated lysine, the sequence cannot be written entirely in standard one-letter amino-acid code.

Research History and Development

Tirzepatide progressed from early-phase type 2 diabetes trials to large phase 3 programs in diabetes and obesity, followed by trials in obesity-related complications and in younger patients.^[1][4][5][6]

Type 2 diabetes

A 2022 systematic review and meta-analysis pooled seven randomized trials with 6,609 adults with type 2 diabetes. At that time, tirzepatide was under review for marketing approval.^[5] It was later approved for type 2 diabetes.^[3] SURPASS-PEDS, a phase 3 trial at 39 sites in eight countries, enrolled 99 participants aged 10 to under 18 years with youth-onset type 2 diabetes and compared two dose levels with placebo over 30 weeks.^[6]

Obesity and related conditions

The global phase 3 SURMOUNT program evaluated tirzepatide for chronic weight management, with regional trials in East Asian populations (SURMOUNT-CN and SURMOUNT-J). Further studies include the phase 2 SYNERGY-NASH trial, the phase 3 SURMOUNT-OSA trial in sleep apnea, and the SUMMIT trial in heart failure with preserved ejection fraction.^[4] The same dose levels are approved for both type 2 diabetes and chronic weight management.^[4]

Mechanisms Studied in Research

Tirzepatide engages the GIP receptor more strongly than the GLP-1 receptor, and at the GLP-1 receptor it favors cAMP signaling over beta-arrestin recruitment. Researchers have proposed that this combination of imbalance and bias contributes to its effects.^[1]

Receptor pharmacology in vitro

A receptor-occupancy analysis found greater engagement of the GIP receptor than of the GLP-1 receptor, which the authors called an imbalanced mechanism of action. Signaling studies showed that tirzepatide mimics native GIP at the GIP receptor. At the GLP-1 receptor it favored cAMP generation over beta-arrestin recruitment and drove weaker receptor internalization than native GLP-1. In primary islets, beta-arrestin 1 limited the insulin response to GLP-1 but not to GIP or tirzepatide.^[1]

Energy balance in mice and humans

In calorie-restricted obese mice, tirzepatide reduced the fall in energy expenditure seen in vehicle-treated and pair-fed controls, and a lower respiratory exchange ratio indicated increased fat oxidation. In a phase 1 trial in people with obesity, tirzepatide appeared to have no effect on metabolic adaptation, but it increased fat oxidation and reduced appetite and calorie intake during an ad libitum test meal compared with placebo.^[7]

Reviewers note that the contribution of GIP receptor activation to cardiovascular risk has not been established, and ongoing outcome trials are expected to clarify it.^[2]

Key Findings From Published Studies

Randomized trials report that tirzepatide lowers HbA1c and body weight compared with placebo and with several active comparators, with gastrointestinal events as the most common adverse effects.^[5][8][9]

Diabetes prevention and comparisons

In the SURMOUNT-1 prediabetes analysis, 1.3% of tirzepatide-treated participants developed type 2 diabetes versus 13.3% on placebo (hazard ratio 0.07). After a 17-week off-treatment period, the figures were 2.4% and 13.7%.^[8] In SURMOUNT-5, waist circumference fell by 18.4 cm with tirzepatide and 13.0 cm with semaglutide.^[9] A US electronic health record cohort of 41,222 adults compared on-treatment weight change and gastrointestinal events between the two drugs in routine care.^[10] A post-hoc MRI analysis of the SURPASS-3 trial assessed thigh muscle volume and muscle fat infiltration over 52 weeks against an insulin comparator.^[11]

Safety signals

A meta-analysis of nine trials with 9,871 participants found no significant increase in pancreatitis with tirzepatide (relative risk 1.46, not significant). A composite of gallbladder or biliary disease was more frequent than with placebo or basal insulin (relative risk 1.97).^[12] A real-world evidence review reported discontinuation rates of 20% to 50% within the first year for GLP-1 receptor agonist-based weight-loss therapies, including tirzepatide, and no clear increase in severe events such as pancreatitis or thyroid disorders.^[13] Observational data also associate this drug class with vitamin D and iron deficiencies, although causality has not been established.^[14]

For a 39-residue lipidated peptide like tirzepatide, batch-specific HPLC and mass-spectrometry certificates of analysis are the practical way to confirm identity and purity.

Regulatory and Research Status

Tirzepatide is an FDA-approved medicine, referred to here only by its generic name, for type 2 diabetes and chronic weight management.^[3][4]

Clinical trials have met regulatory requirements for cardiovascular safety in high-risk patients, and several large cardiovascular outcome trials are under way.^[2] Reviewers list long-term safety, efficacy, cardiovascular outcomes and cost-effectiveness as areas still being studied.^[4] Real-world researchers have also called for studies of the effects of stopping treatment and of rare outcomes such as eye disease.^[13]

Outside its approved medical uses and registered clinical trials, material described as tirzepatide is intended for laboratory research only. This page summarizes published findings and does not provide guidance on human use.